Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

Articles

The latest news for pharma industry insiders.

Pharma Pulse 1/24/25: The Ups and Downs of AI for Pharma Investors, Defining Diagnostic Criteria for Clinical Obesity & more

. He can be reached at nsaraceno@mjhlifesciences.com.

A cross-sectional study investigates the impact of Dobbs v Jackson’s Women’s Health Organization on national support and personal interest.  

How Advance Provision, OTC Access to Abortion Medication Changed Pre- and Post-Dobbs Ruling

Videos

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Amanda Salindong, associate director of channel & distribution at Alnylam Pharmaceuticals, explains the premise of the Trade & Channel sessions that she participated in, along with some of the audience feedback that she received.


Fostering Relationships and Leadership Within the Trade Sector

Pharma Pulse 1/23/25: Key Markets Investors Can’t Ignore, Moderna Gets $590 Million for Bird Flu Vaccine Development & more

What factors influence their likelihood of receiving this form of obesity treatment?

The Association Between Semaglutide Initiation and Obese Individuals Without Diabetes

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, describes the importance of the patient within the pharma supply chain.

Focusing on the Patient

Pharma Pulse 1/22/25: How Politics Impact Investors, Pharmacies Struggle Amid California Wildfires & more

The latest AARP report concludes that plan members who hit this amount are expected to see savings, even when premiums are considered. 

Analysis: Medicare Part D Enrollees Who Reach the $2,000 OOP Spending Cap to Save an Average of $2,474 Nationally 

In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, discusses the origins of the compounding pharmacy, including what it seeks to accomplish.  

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs